Alkermes plc completed its acquisition of Avadel Pharmaceuticals plc on February 12, 2026, closing the deal under an Irish High Court‑sanctioned scheme of arrangement. The transaction valued Avadel at up to $2.1 billion, comprising $775 million in cash and $1.525 billion in term loans. Avadel shareholders received $21.00 in cash per share plus a contingent value right (CVR) that entitles them to an additional $1.50 per share if a specified milestone is met.
The acquisition brings LUMRYZ, Avadel’s FDA‑approved once‑at‑bedtime oxybate for narcolepsy, into Alkermes’ commercial portfolio. LUMRYZ is the first product in its class to offer a single nightly dose, providing a distinct advantage over Jazz Pharmaceuticals’ twice‑nightly oxybates. The addition complements Alkermes’ own narcolepsy pipeline, notably the orexin‑2 receptor agonist alixorexton, and positions the company to accelerate commercialization and broaden market reach.
Financially, the deal is expected to be accretive to Alkermes’ 2026 results. Alkermes reported $1.56 billion in revenue in 2025, a 6% decline from 2023, while Avadel’s LUMRYZ generated $77.5 million in net product revenue in Q3 2025, up 55% year‑over‑year. The combination is projected to enhance Alkermes’ revenue growth profile and support a robust balance sheet, with the company planning to pay down the debt quickly using cash flows from the newly acquired business.
Alkermes plans to integrate Avadel’s commercial and research‑and‑development operations to accelerate product commercialization and leverage synergies across the sleep‑medicine segment. The integration strategy is designed to broaden market reach, streamline supply chains, and combine the strengths of both companies’ sales forces.
Richard Pops, Alkermes CEO, said: "With the close of this acquisition, Alkermes achieved an important milestone in the continued advancement of our strategy, accelerating our entry into the commercial sleep medicine market at a pivotal moment as we work to initiate the planned phase 3 program for alixorexton in narcolepsy this quarter." Greg Divis, Avadel CEO, added: "LUMRYZ strengthened its market position and delivered accelerated growth in revenue, positive cash flow and momentum in a second quarter, supported by its strong and growing foundation of prescribers and patients and our 2025 commercial investments."
Alkermes will provide its 2026 financial expectations for the combined organization on February 25, 2026, offering investors a clearer view of the long‑term value creation expected from the acquisition.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.